What are Biopharmaceuticals?
Biopharmaceuticals are advanced medicines produced using living cells. A key example is therapeutic antibodies, which are proteins engineered to bind precisely to specific disease targets, much like the antibodies in our natural immune system.
What are Biosimilars?
Biosimilars are biological medicines that are highly similar to already approved reference biologics. They demonstrate no clinically meaningful differences in terms of quality, safety, and efficacy. Celltrion has successfully pioneered the development of mAb biosimilars, offering patients around the world effective and more accessible treatment options.
What are Novel Therapeutics?
With accumulated know-hows on antibody biosimilar development, we are developing new therapeutics by discovering new antibodies. In addition, as part of our continuous effort to expand treatment options, we are developing new biologics combined with Antibody-Drug Conjugates (ADCs) and multispecific antibody technology.
-
Novel Antibody Therapeutics
Novel antibody therapeutics focus on discovering new antibodies that can bind to biomarkers that are shown on certain diseases. Such novel therapeutics are highly effective and can maximize treatment efficacy when used with biosimilars to be developed.
-
ADC Therapeutics
Antibody-Drug Conjugates (ADCs) are highly targeted biopharmaceuticals built by combining a potent small molecule drug with an antibody that binds to specific types of antigens. Current treatments for curing cancers are highly effective, yet their toxicity may affect normal cells as well and cause side effects. ADCs, on the other hand, can deliver cytotoxic small molecules to target lesion without damaging normal tissues increasing treatment efficiency and safety.
-
Multispecific Antibody Therapeutics
Multispecific antibody therapeutics are modified so that antibodies can recognize two or more antigens allowing better detection of the lesion. Such therapeutics are expected to be more effective than the existing treatments because multiple antibodies bind to two or more epitopes, inhibiting the growth of cancer cells induced by the targets or stimulating cancer cell death by attaching immune cells such as T cells to cancer cells.
